Capricor Therapeutics Inc. has released a new investor presentation outlining key developments in its pipeline and financial position. The company highlighted progress in its Duchenne muscular dystrophy (DMD) program, including the anticipated topline data from the HOPE-3 Phase 3 clinical trial expected in the fourth quarter of 2025. Capricor also provided updates on its StealthX exosome platform, including ongoing Phase 1 studies in collaboration with NIAID. The presentation notes a cash balance of $123 million as of June 30, 2025, with a projected operational runway into the fourth quarter of 2026. Additionally, Capricor stands to receive up to $80 million in milestone payments upon potential U.S. approval of its DMD therapy, with additional sales-based milestones and the possibility of monetizing a Priority Review Voucher. You can access the full presentation through the link below.